Klaria Pharma Holding AB (KLAR) - Total Assets
Based on the latest financial reports, Klaria Pharma Holding AB (KLAR) holds total assets worth Skr30.01 Million SEK (≈ $3.23 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check KLAR total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Klaria Pharma Holding AB - Total Assets Trend (2014–2025)
This chart illustrates how Klaria Pharma Holding AB's total assets have evolved over time, based on quarterly financial data. Check Klaria Pharma Holding AB cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Klaria Pharma Holding AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Klaria Pharma Holding AB's total assets of Skr30.01 Million consist of 5.9% current assets and 94.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr342.00K | 0.8% |
| Accounts Receivable | Skr2.05 Million | 5.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr591.00K | 1.5% |
| Intangible Assets | Skr37.78 Million | 92.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Klaria Pharma Holding AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Klaria Pharma Holding AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Klaria Pharma Holding AB's current assets represent 5.9% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2025, down from 983.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 92.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 92.7% of total assets.
Klaria Pharma Holding AB Competitors by Total Assets
Key competitors of Klaria Pharma Holding AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Klaria Pharma Holding AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.06 | 1.64 |
| Quick Ratio | 0.06 | 0.06 | 1.73 |
| Cash Ratio | 0.00 | 0.03 | 1.54 |
| Working Capital | Skr-38.43 Million | Skr-49.44 Million | Skr16.42 Million |
Klaria Pharma Holding AB - Advanced Valuation Insights
This section examines the relationship between Klaria Pharma Holding AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 40.46 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | -28.8% |
| Total Assets | Skr40.77 Million |
| Market Capitalization | $20.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values Klaria Pharma Holding AB's assets below their book value (0.51x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Klaria Pharma Holding AB's assets decreased by 28.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Klaria Pharma Holding AB (2014–2025)
The table below shows the annual total assets of Klaria Pharma Holding AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr40.77 Million ≈ $4.39 Million |
-28.81% |
| 2024-12-31 | Skr57.27 Million ≈ $6.16 Million |
-21.49% |
| 2023-12-31 | Skr72.95 Million ≈ $7.85 Million |
-39.35% |
| 2022-12-31 | Skr120.27 Million ≈ $12.94 Million |
+1.66% |
| 2021-12-31 | Skr118.31 Million ≈ $12.73 Million |
-10.65% |
| 2020-12-31 | Skr132.41 Million ≈ $14.25 Million |
+30.16% |
| 2019-12-31 | Skr101.73 Million ≈ $10.95 Million |
-4.26% |
| 2018-12-31 | Skr106.25 Million ≈ $11.43 Million |
-31.83% |
| 2017-12-31 | Skr155.87 Million ≈ $16.77 Million |
-3.80% |
| 2016-12-31 | Skr162.03 Million ≈ $17.44 Million |
-8.39% |
| 2015-12-31 | Skr176.88 Million ≈ $19.04 Million |
+353664.00% |
| 2014-12-31 | Skr50.00K ≈ $5.38K |
-- |
About Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; a… Read more